Guggenheim Reiterates Buy on ANI Pharmaceuticals, Maintains $72 Price Target
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Vamil Divan has reiterated a 'Buy' rating on ANI Pharmaceuticals (NASDAQ:ANIP) and maintained a price target of $72.
October 19, 2023 | 5:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Guggenheim analyst has reiterated a 'Buy' rating on ANI Pharmaceuticals and maintained a price target of $72.
The reiteration of a 'Buy' rating by a Guggenheim analyst and the maintenance of a $72 price target indicates a positive outlook for ANI Pharmaceuticals. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100